Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C
Go back to Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C| HERCULES TECHNOLOGY GROWTH CAPITAL, Inc. (NYSE: HTGC) | Delayed: 17.63 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.63 | 52 Week High | $14.00 | |||
| Open | $17.63 | 52 Week Low | $9.92 | |||
| Day High | $17.63 | P/E | 10.02 | |||
| Day Low | $17.63 | EPS | $1.76 | |||
| Volume | 694 | |||||
